返回 Agenda
Closing Session: Panel Discussion
Session Chair(s)
James D. Thompson, PHD
CMC Therapeutic Area Lead, Moderna Therapeutics , United States
This panel discussion is meant to highlight the challenges and issues with the development of oligonucleotide-based products in general, and as brought forth at this conference. The intention is to transform this discussion into action-oriented objectives to address the regulatory and industry issues and challenges affecting us all.
Speaker(s)
James Wild, PHD, MS
Pharmacologist, CDER, FDA, United States
Session Co-Chair
Emily Place, PHD, MPH
Senior Consultant, Aclairo Pharmaceutical Development Group, United States
Panelist
Jeffery Engelhardt, DVM, PHD
Vice President, Pathology and Nonclinical Drug Safety, Ionis Pharmaceuticals, Inc., United States
Panelist
Arthur M. Krieg, MD
CEO and CSO, Checkmate Pharmaceuticals, United States
Panelist
Arthur A. Levin, PHD
Distinguished Scientist, Avidity Biosciences, United States
Panelist
Daniel Capaldi, PHD
Vice President, Analytical and Process Development, Ionis Pharmaceuticals, Inc, United States
Panelist
Kim Tyndall
President, CMC Tyndall Consultant LLC, United States
Panelist